封面
市場調查報告書
商品編碼
921259

高鉀血症治療的全球市場:成長,趨勢,及預測

Hyperkalemia Treatment Market - Growth, Trends, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

高鉀血症,是由於各種藥物的使用,腎功能障礙,以及電解質不均衡等其他原因可能發生的威脅生命的疾病。癌症和腸胃疾病的盛行率增加伴隨的高鉀血症的增加,對研究開發的關注高漲和策略性聯盟的增加,使高鉀血症治療市場成長。但,藥物的高成本是妨礙該市場成長的要素。

本報告提供全球量鉀血症市場的相關調查,市場機會和趨勢,成長及阻礙因素,各藥物、疾病類型、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 高鉀血症的盛行率增加
    • 研究開發的關注高漲和策略性聯盟的增加
  • 阻礙市場要素
    • 藥物的高成本
  • 波特的五力分析

第5章 市場區隔

  • 各藥物
    • Sodium zirconium cyclosilicate
    • Patriomer
    • Beta2促效劑
    • 利尿劑
    • 聚苯乙烯磺酸鹽酸鈉
    • 其他
  • 各疾病類型
    • 急性高鉀血症
    • 慢性高鉀血症
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • AstraZeneca Plc
    • Ardelyx
    • Perrigo
    • Vifor Pharma Management Ltd.
    • Sanofi SA

第7章 市場機會及今後趨勢

簡介目錄
Product Code: 67105

The increasing prevalence rates of acute hyperkalemia and chronic hyperkalemia are due to the upsurge in geriatric population, globally. The aging population and advances in medical technology are likely to contribute to the increasing prevalence of heart failure and chronic kidney diseases, and consequently, a larger pool of patients is likely to be at risk for hyperkalemia. According to the data from the World Population Prospects: The 2017 Revision, the number of older people, those aged 60 years or above, is expected to be more than double by 2050 and more than triple by 2100, rising from 962 million in 2017 to 2.1 billion in 2050 and 3.1 billion in 2100.

Hyperkalemia has been reported in around 5% of the general population, worldwide. According to the National Kidney Foundation, in heart failure patients with chronic kidney disease (CKD), the prevalence of hyperkalemia can be up to 20%, and it is associated with an increased risk of mortality and major adverse cardiovascular events. According to the United States Renal Data System (USRDS) (2018), the overall prevalence of CKD (Stages 1-5) among the adult general population in the United States was 14.8% during 2013-2016.

Potassium is regarded as one of the most effective alkalinizing agents for the treatment of hyperkalemia. Moreover, its use in the management of acute and chronic hyperkalemia, related to advanced medical illness, is considered as the standard care in most parts of the world.

Thus, increase in the number of patients undergoing treatment of hyperkalemia is likely to drive the growth of the market.

Key Market Trends

Chronic Hyperkalemia Dominates the Global Hyperkalemia Treatment Market

Chronic hyperkalemia from impaired renal excretion may involve one or more of the conditions, such as decreased mineralocorticoid activity, decreased distal Na+ delivery, and CCD dysfunction. Considered individually, these pathophysiologic processes generally do not create chronic hyperkalemia, but together their effects become clinically significant.​ Chronic hyperkalemia is one of the most prevalent disease conditions among patients suffering from CKDs. As per the National Kidney Foundation, more than 37 million people in the United States have CKDs, and over 80% of them do not know they have it. ​Moreover, the management of chronic hyperkalemia requires confirmation, increased laboratory surveillance, dietary review and counseling, a review of medications (prescribed, over-the-counter, and herbal), and, if needed, a potassium-lowering medication and/or a diuretic.​ As the kidney function declines, the prevalence in patients with CKDs increases; it ranges from 5% to 50% in the patients.​Overall, the chronic hyperkalemia segment of the market studied is expected to grow over the forecast period. This is expected to be fueled by the increasing prevalence of chronic hyperkalemia, with an upsurge in geriatric population levels and related ailments.​

North America Dominates the Global Hyperkalemia Treatment Market

The presence of leading market players, the high prevalence of disease-related conditions, favorable healthcare policies, and high disposable income of the patients bolster demand for advanced therapeutic options, thereby, are expected to contribute to the dominance of the United States, throughout the forecast period.​ Moreover, the growing incidence of hyperkalemia and the rising number of geriatric population are some major factors aiding the growth of the market. Thus, the huge patient population is anticipated to increase the number of patients who opt for treatment, which, in turn, is expected to support growth in the near future.​ For instance, in the United States, the federal government has been running various awareness campaigns through various initiatives, which is expected to have a positive impact on the market studied. ​Hence, this increasing adoption of a patient-centric approach by healthcare payers is expected to drive the US hyperkalemia treatment market, during the forecast period.​

Competitive Landscape

The hyperkalemia market is consolidated, dominated by a few players. The hyperkalemia market underwent extensive changes with the introduction of Veltassa at the beginning of 2016, which represented the first new therapy for the treatment of hyperkalemia in over 50 years. Few key market players in the market are AstraZeneca PLC, Ardelyx, Vifor Pharma Management Ltd, Sanofi SA, and Perrigo Company PLC.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Hyperkalemia
    • 4.2.2 Rising Focus on Research and Development and Increasing Number of Strategic Alliances
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug
    • 5.1.1 Sodium Zirconium Cyclosilicate
    • 5.1.2 Beta2 Agonist
    • 5.1.3 Sodium Polystyrene Sulfonate
    • 5.1.4 Other Drugs
  • 5.2 By Type of Disease
    • 5.2.1 Acute Hyperkalemia
    • 5.2.2 Chronic Hyperkalemia
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca PLC
    • 6.1.2 Ardelyx
    • 6.1.3 Perrigo Company PLC
    • 6.1.4 Vifor Pharma Management Ltd
    • 6.1.5 Sanofi SA
    • 6.1.6 Relypsa Inc.
    • 6.1.7 Odan Laboratories Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS